Pemvidutide: Research & Studies

Research Overview#

Pemvidutide has been evaluated in two Phase 2b programs targeting different indications. The IMPACT trial focused on MASH resolution in patients with advanced fibrosis, while the MOMENTUM trial assessed weight loss in obesity. Both reported positive results in 2025.

IMPACT Phase 2b (MASH)#

The IMPACT trial enrolled 212 adults with biopsy-confirmed F2/F3 MASH. At 48 weeks, 59.1% of patients receiving 1.2 mg achieved MASH resolution without worsening fibrosis, compared to 16.7% with placebo. Liver fat reduction by MRI-PDFF reached 54.7% at the 1.8 mg dose.

MOMENTUM Phase 2b (Obesity)#

The MOMENTUM trial demonstrated dose-dependent weight loss, with 15.6% total body weight reduction at 2.4 mg at 48 weeks. A key finding was that 78.1% of weight loss came from fat mass, suggesting favorable body composition changes.

Evidence Quality#

Research Evidence Context#

Pemvidutide belongs to the Metabolic category of research peptides. The research evidence for Pemvidutide spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Pemvidutide:

Pemvidutide Phase 2b IMPACT Trial in MASH#

Authors: Altimmune investigators (2025) — American Association for the Study of Liver Diseases (AASLD)

Phase 2b study in 212 adults with biopsy-confirmed F2/F3 MASH. Patients received pemvidutide 1.2 mg or 1.8 mg weekly for 48 weeks. The 1.2 mg dose achieved 59.1% MASH resolution without worsening fibrosis.

Key Findings:

• 59.1% MASH resolution at 1.2 mg vs 16.7% placebo
• 52.1% MASH resolution at 1.8 mg
• 54.7% liver fat reduction by MRI-PDFF at 1.8 mg at 48 weeks
• Fibrosis improvement observed across doses

Limitations: Conference presentation data; full peer-reviewed publication pending; 48-week duration; no active comparator

Pemvidutide Phase 2b MOMENTUM Trial in Obesity#

Authors: Altimmune investigators (2025) — Conference presentation (Altimmune)

Phase 2b study evaluating pemvidutide 1.2, 1.8, and 2.4 mg weekly in adults with obesity or overweight with comorbidities for 48 weeks.

Key Findings:

• 15.6% total body weight loss at 2.4 mg at 48 weeks
• 78.1% of weight loss from fat mass at 2.4 mg
• No dose titration required across all dose groups
• Dose-dependent weight loss across 1.2, 1.8, and 2.4 mg groups

Limitations: Conference data; peer-reviewed publication pending; relatively small sample sizes per dose group

Pemvidutide Effects on Liver Fat in MASLD#

Authors: Rosenstock J, et al. (2024) — Journal of Hepatology

Published study evaluating pemvidutide effects on liver fat reduction in patients with metabolic dysfunction-associated steatotic liver disease.

Key Findings:

• Significant liver fat reduction by MRI-PDFF
• Dose-dependent improvements in hepatic steatosis
• Weight loss accompanied by liver fat improvements

Limitations: Earlier-phase data; larger confirmatory trials needed

Evidence Quality Assessment#

The overall evidence level for Pemvidutide is classified as moderate. There is meaningful clinical evidence from Phase 2 or similar trials, though larger confirmatory studies may be needed.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Pemvidutide have been identified:

• No Phase 3 data yet available
• No head-to-head comparison with resmetirom or survodutide for MASH
• Long-term fibrosis regression data beyond 48 weeks not available
• Cardiovascular outcomes data not yet studied
• Optimal dose for dual obesity/MASH indication not established

Addressing these research gaps will be important for establishing a more complete understanding of Pemvidutide's therapeutic potential and safety profile.

Related Reading#

• Pemvidutide overview and research guide
• Pemvidutide dosing protocols
• Pemvidutide molecular structure